Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 3.11B 2.78B 2.59B 2.35B 4.42B 295B 4.45B 31B 12.14B 153B 11.67B 11.42B 492B P/E 2026 *
-14.6x
P/E 2027 * 924x
Enterprise Value 2.77B 2.48B 2.31B 2.09B 3.94B 263B 3.97B 27.64B 10.82B 137B 10.41B 10.18B 439B EV / Sales 2026 *
3.84x
EV / Sales 2027 * 2.84x
Free-Float
97.31%
Yield 2026 *
-
Yield 2027 * -
1 day-4.81%
1 week-4.44%
Current month-9.91%
1 month-10.70%
3 months+19.41%
6 months-2.52%
Current year-13.51%
1 week 70.32
Extreme 70.32
76.64
1 month 70.32
Extreme 70.32
80.01
Current year 53.89
Extreme 53.89
91.53
1 year 53.89
Extreme 53.89
91.53
3 years 12.57
Extreme 12.57
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2018
Director of Finance/CFO 64 24/04/2023
Chief Tech/Sci/R&D Officer 47 04/11/2024
Director TitleAgeSince
Chairman 48 02/12/2022
Director/Board Member 71 01/12/2019
Director/Board Member 80 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
15/9/26 Exercice

Director

604 0.0014%
15/9/26 Exercice

Director

12,902 0.0294%
15/9/26 Exercice

Director

402 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-4.81%-4.44%+0.68%+445.61% 3.11B
-1.36%+0.78%+42.36%+91.48% 1,040B
-5.73%-2.42%+30.23%+58.50% 599B
-2.40%+2.88%+19.13%+85.43% 485B
-2.39%+0.03%+65.67%+36.51% 350B
+0.56%+0.47%+26.38%+43.45% 345B
+0.78%+0.23%+15.63%+37.96% 272B
+0.03%-2.32%-6.59%+8.44% 244B
-1.13%+2.54%+41.19%+45.32% 223B
-1.67%+2.56%+25.13%+90.50% 183B
Average -1.53%+1.70%+25.98%+94.32% 374.59B
Weighted average by Cap. -1.10%+2.30%+32.03%+64.04%

Financials

2026 *2027 *
Net sales 721M 644M 600M 544M 1.02B 68.44B 1.03B 7.19B 2.82B 35.6B 2.71B 2.65B 114B 927M 828M 772M 700M 1.32B 88.02B 1.33B 9.25B 3.62B 45.77B 3.48B 3.41B 147B
Net income -218M -195M -182M -165M -310M -20.74B -313M -2.18B -853M -10.78B -820M -802M -34.61B 6.9M 6.16M 5.74M 5.21M 9.8M 655M 9.88M 68.8M 26.93M 341M 25.91M 25.34M 1.09B
Net Debt -336M -300M -280M -254M -478M -31.92B -481M -3.35B -1.31B -16.6B -1.26B -1.24B -53.27B -476M -425M -396M -359M -676M -45.15B -681M -4.74B -1.86B -23.48B -1.79B -1.75B -75.35B
Projected Income Statement - Annual - Tarsus Pharmaceuticals, Inc.
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
13/10/26 US$70.82 -4.81% 1,632,816
12/10/26 US$74.40 +1.69% 1,463,048
09/10/26 US$73.16 +1.30% 481,753
08/10/26 US$72.22 -1.89% 642,111
07/10/26 US$73.61 -0.67% 542,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Tarsus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
70.82USD
Average target price
99.50USD
Spread / Average Target
+40.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tarsus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. TARS Stock